Research programme: dihydrocostatolide - National Cancer Institute/Sarawak MediChem

Drug Profile

Research programme: dihydrocostatolide - National Cancer Institute/Sarawak MediChem

Alternative Names: (-)-Dihydrocalanolide B; 7,8-Dihydrocostatolide; Dihydrocodstatolide; NSC 661123

Latest Information Update: 02 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Class Antivirals; Coumarins; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 01 Oct 1999 A study has been added to the antimicrobial activities section
  • 30 Jan 1996 Preclinical development for HIV infections treatment in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top